You searched for "gases"
Rotational stability of angle supported phakic IOL
The authors evaluate 50 eyes of 28 patients that underwent an angle fixated phakic intraocular lens (IOL) implantation (Acrysof Cachet). All eyes had moderate to high myopia (-5.25 to-19.63 dioptres) and IOL sizing was performed as per the manufacturer’s recommendation....
Diclofenac versus Bromfenac after cataract surgery
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used after cataract surgery to reduce inflammation and cystoid macular oedema (CMO). Diclofenac 0.1% is used three to five times daily for 28 days and Bromfenac 0.09% twice daily for 14 days postoperatively. The...
Delayed EPBRT efficacy in retinoblastoma
This is a retrospective medical records review of 50 patients (54 eyes) with retinoblastoma (RB), who received I-125 episcleral plaque brachytherapy (EPBRT) prior to (primary) or following chemoreduction (delayed) alone and in combination with non-irradiative focal therapy. Fifty-six plaques were...
Efficacy of IVC injection in the treatment of ROP
This is a retrospective consecutive case series of patients who received intravitreal conbercept (IVC) as a primary treatment from June 2015 to July 2016 for treatment of retinopathy of prematurity (ROP). Forty-eight eyes of 24 patients were included in the...
Topical nonsteroidal ant-inflammatory drugs (NSAIDs) in patients undergoing cataract surgery
Inflammation is a major risk factor for the development of cystoid macular oedema (CMO) after cataract surgery, leading to breakdown of the blood-retina barrier. There is a correlation between severity of CMO and level of postoperative inflammation. Laser flare meter...
Treatment efficacy of stage 4 ROP
This study aimed to determine the efficacy of combined vitrectomy and anti-VEGF injection for advanced stage 4 ROP with extensive neovascular proliferation (NF). The study included nine infants; six bilateral and three unilateral. Seven were female and the mean gestational...
ROP anti-VEGF treatment review
The purpose of this review was to consider data relating to risks and benefits of the use of anti-VEGF treatment for retinopathy of prematurity (ROP) over the past five years of 2015-2020. Ocular benefits include treatment of aggressive posterior ROP,...
